Jasper Therapeutics(US:JSPR) Globenewswire·2025-09-21 13:57Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Jasper Therapeutics, Inc. during the specified Class Period from November 30, 2023, to July 3, 2025, due to alleged misleading statements and failures to disclose critical information [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Jasper Therapeutics lacked necessary controls and procedures for third-party manufacturers, which could lead to non-compliance with cGMP regulations [5]. - It is alleged that this failure increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of Jasper's products, particularly briquilimab [5]. - The lawsuit asserts that Jasper's business and financial prospects were overstated, and public statements made by the defendants were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Jasper Therapeutics securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 18, 2025, to represent the interests of other class members in the litigation [1][3]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability and experience in handling such cases [4].